Gemtuzumab Ozogamicin represents a unique development in the therapy of relapsed myeloid malignancy, mainly severe myeloid leukemia (AML). This novel conjugate combines a humanized molecule targeting to the CD33 https://www.targetmol.com/compound/gemtuzumab